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prior to that timepoint. There was a positive correlation between the number of CVEs before and during
LA therapy. No differences were seen with respect to lipid concentrations, even after a correction of LDL-
C concentrations for the LDL-C transported with Lp(a) particles. LA sessions effectively reduced both
LDL-C and Lp(a). Lp(a) levels measured before LA sessions were lower than those measured initially.
It appeared difficult to reach the target values for LDL-C published in the ESC/EAS Guideline in 2019,
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Abstract: Lipoprotein apheresis (LA) is an effective tool to reduce cardiovascular events (CVEs) in
high-risk patients with elevations of low density lipoprotein-cholesterol (LDL-C) and/or Lipoprotein(a)
(Lp(a)). All patients included into this retrospective analysis had experienced CVEs before the start of
the LA therapy. We compared personal and lab data in two groups: CVEx/0 (n 60) with no new events
during LA therapy, CVEx/1+ (n 48) with at least one new event. Patients of Group CVEx/1+ were
about 5 years older when they had started the extracorporeal therapy, and they experienced more
CVEs prior to that timepoint. There was a positive correlation between the number of CVEs before
and during LA therapy. No differences were seen with respect to lipid concentrations, even after
a correction of LDL-C concentrations for the LDL-C transported with Lp(a) particles. LA sessions
effectively reduced both LDL-C and Lp(a). Lp(a) levels measured before LA sessions were lower
than those measured initially. It appeared difficult to reach the target values for LDL-C published in
the ESC/EAS Guideline in 2019, although all patients were maximally treated including drugs when
tolerated. In conclusion, it will be important to initiate an LA therapy earlier, at least after a second
CVE and at a younger age.
Keywords: lipoprotein apheresis; cardiovascular events; LDL-cholesterol; LDL-cholesterol corrected
for its content in Lipoprotein(a) particles; Lipoprotein(a); targets for LDL-cholesterol
1. Introduction
In high-risk patients lipoprotein apheresis (LA) is the last resort therapy to prevent new
cardiovascular events (CVEs) [1]. In two studies—one with a retrospective evaluation and one
with a prospective design—the high effectiveness of LA with respect to a reduction of CVEs by more
than 80% was shown when comparing the situation before the start of the extracorporeal therapy
and during this therapy in patients with elevated lipoprotein(a) (Lp(a)) levels [2–4]. In the last years,
the number of patients with this indication was constantly increasing in Germany. In patients who
show only high LDL-cholesterol (LDL-C) concentrations and whose Lp(a) was absent or in the normal
range the efficiency of LA with respect to CVEs is less [5].
When the Federal Joint Committee (Gemeinsamer Bundesausschuss) published its decision to
accept an LA in patients with high Lp(a) levels, a randomized controlled study was requested [6].
However, the ethics committee did not allow this kind of study to be performed. Thus, the usual
way to compare outcome data in LA patients is to look at the situation before and during the
extracorporeal therapy.
The aim of this evaluation was to look for factors that may be associated with the incidence of
new CVEs in LA patients. In general, both personal factors and standard laboratory data have been
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taken into consideration. A special focus was made on the concentrations of LDL-C after a correction
for the LDL-C which is contained in the Lp(a) particles.
About 10 years ago, we asked the same question as we are now [7]. However, since then the
number of patients at our facility has more than doubled; all new patients starting the LA therapy
in the last years had an elevation of Lp(a) and the quality of the measurement of this parameter
was improved.
2. Material and Methods
At the timepoint of this evaluation (May 2019) a total of 132 patients were treated with LA
at our department. Four patients were not included because two of them had undergone a heart
transplantation and the other two did not suffer from CVEs (but had significant atherosclerotic lesions
at several vessel regions and belonged to families where relatives had CVEs). Moreover, in order to
ensure an observation time of at least more than 1 year, during the LA treatment, patients who started
LA in 2018 were also not taken into consideration (n 20). The remaining 108 patients were subdivided
into two groups: 1. CVEx/0 patients reported events before the start of LA and had no events during
LA (n 60), 2. CVEx/1+ patients reported events before the start of LA and suffered from at least one
CVE at the follow-up during LA (n 48). The following CVEs were taken into account: myocardial
infarction, stroke, transitory ischemic attack, occlusions of arteries, interventions (stents, operations) at
various vessel territories. The majority of new events during LA were stenting.
Lipid concentrations (triglycerides (TG), high density lipoprotein-cholesterol (HDL-C),
LDL-cholesterol (LDL-C)) have been measured using routine methods (Cobas8000-System from Roche,
Basel, Switzerland.). For Lp(a) measurement the Immunoassay for Lp(a) (WHO/IFCC International
Reference Reagent) – SRM 2B (Roche/Hitachi Cobas c 701/702) was used.
The directly measured LDL-C reflects two compartments: 1. Transported with the LDL particles,
2. Transported with the Lp(a) particles. Drugs decreasing LDL-C concentrations exert an effect on
the LDL-C compartment which is contained in the LDL particles. In order to get an information
about this compartment we subtracted the LDL-C in Lp(a) from the measured LDL-C. Two steps
were needed for this calculation: 1. Lp(a) levels which are given in nmol/L had to be converted into
mg/dL (by dividing by 2.4)—data show that this calculation is evidently not correct, 2. We estimated
the LDL-C content in the Lp(a) particles to be equivalent to 30%—which is an accepted estimation.
The formula used was: LDL-Ccorrected (LDL-Ccorr) = LDL-C - 0:3 × Lp(a) mass [8]. Thus, the so-called
LDL-Ccorr concentrations may not be exact but they provide an idea about the compartment which
can be optimized by drugs.
In order to describe the lipid load in the patients during LA therapy, interval mean values have
been calculated for LDL-C according to Kroon [9] and for Lp(a) according to Tselmin [10].
At our department, 6 different LA methods have been used (Table 1) [11].
Table 1. LA methods used at our center.
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Up to now, no clear indication for a certain LA method exists. Thus, patients started treatment
with a given LA method for which a free machine was available. In some patients, the LA method was
switched to another one when the effectiveness with respect to lipid lowering rates was not sufficient
or when adverse effects occurred. In this study, this switching was not documented. The vast majority
of our patients were treated with LA weekly.
We report lipid concentrations measured before the first LA (the lipid levels after the first LA
session are not representative, because usually at this session the treated whole blood or plasma volume
has to be reduced in order to ensure a high safety level for the patient) and LDL-C and Lp(a) levels
observed before and after a single LA session performed in May 2019.
The majority of our patients were taking lipid-lowering drugs (statins when tolerated, ezetimib,
PCSK9 inhibitors in some patients). Usually this therapy had been already started following CVEs
(mostly several months before the initiation of the LA therapy) and was modified in those patients
whose LDL-C values appeared to be rather high during the extracorporeal therapy.
The numbers of lipid-lowering drugs were in the groups: 1. CVEx/0 at the start of LA therapy:
statins 54 (90%), ezemitib 28 (46.7%), PCSK9 inhibitors 0, in May 2019: statins 46 (76.6%), ezetimib 27
(45%), PCSK9 inhibitors 9 (15%); 2. CVEx/1+ at the start of LA therapy: 42 (87.5%), ezetimib 23(47.9%),
PCSK9 inhibitors 2 (4.2%), in May 2019: statins 38 (79.2%), ezetimib 24 (50%), PCSK9 inhibitors 13
(27.1%).
For comparisons of numerical data, the one-way ANOVA was used (IBM SPSS Statistics Version
25.0, Armonk, NY, USA) with post-hoc test according to Bonferroni. A correlation analysis according
to Pearson was performed in Group CVEx/1x between CVEs before the start of LA therapy and CVEs
during LA therapy. A p-level below 0.05 was considered to be significant.
The study had been approved by the local ethics committee (EK 82022019).
3. Results
3.1. Groups Defined by CVEs during LA Treatment
Group CVEx/0 consisted of 60 patients (42 males, 18 females), the mean age at the first LA session
was 55 years (range 29–75 years). In the mean, patients of this group were treated with LA for 5.1 years
(range 1.4–21.8 years. In total, 48 patients (28 males, 20 females) belonged to group CVEx/1+, their mean
age at first LA session was 60 years (range 41–75 years), and the LA treatment was performed for 6.3
years in the mean (range 1.4–26.4 years).
The age difference between both groups was statistically significant (p 0.041). The gender
distribution and the duration of the LA therapy were not different.
In the total population, before LA therapy 2.71 CVEs occurred per patient in the mean, during the
mean follow-up time of more than 5 years during LA this number amounted to 1.06 CVEs per patient.
This means a relative reduction of CVEs by about 61%. Nevertheless, the majority of our patients did
not develop new CVEs during the extracorporeal therapy (Group CVEx/0).
The mean numbers of CVEs per patient in both groups are given in Figure 1.
The number of CVEs before the start of the LA therapy was statistically significantly different
(p 0.002) between the two groups. Moreover, in the Group CVEx/1+ the number of CVEs before LA
therapy positively correlated with the CVEs number during LA treatment (correlation coefficient 0.331,
p 0.022).
3.2. Lipid Concentrations in the CVE-Groups
Figure 2 depicts the LDL-C concentrations measured before the first LA session (reflecting starting
conditions), LDL-C levels before and after a single LA session in May 2019, interval mean values and
the corresponding LDL-Ccorr concentrations (which were corrected for the LDL-C contained in the
Lp(a) particles at the given timepoint).
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Figure 1. Number of CVEs per patient (means, standard deviations) before the start of LA therapy
(CVEsbef) and during LA therapy (CVEsdur) in both groups.
 
 
Figure 2. LDL-C and corresponding LDL-Ccorr levels (means, standard deviations) at first LA session
and at an LA session in 2019 (before (pre) and after (post) one single LA session).
Initial LDL-C concentrations ranged in Group CVEx/0 between 0.38 and 7.20 mmol/L, before the
LA session in 2019 between 0.53 und 4.95 mmol/L and after this session between 0.14 and 1.60 mmol/L.
In Group CVEx/1+, the initial LDL-C was between 0.62 and 6.11 mmol/L, before the LA session in 2019
between 0.59 and 5.91 mmol/L and after the LA session between 0.13 and 2.56 mmol/L.
The LA therapy was very effective with respect to acute reductions of LDL-C. Lp(a) levels were
also measured at the initiation of the LA therapy and at the same session as mentioned above in 2019
(Figure 3).
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Figure 3. Lp(a) levels at first LA session and at an LA session (means, standard deviations) in 2019
(before (pre) and after (post) one single LA session) Patients with absent or low Lp(a) levels (Lp(a) was
not measured in the clinical routine any longer): Group CVEx/0: 2, Group CVEx/1+: 10.
In contrast to the situation with LDL-C, a longer lasting LA therapy decreases the Lp(a)
concentrations assessed before the LA sessions. Acute reductions of Lp(a) were also excellent.
In Table 2, the initial HDL-C and TG concentrations are given. Both parameters are influenced by
LA but they do not represent target levels for the extracorporeal therapy. That is why no follow-up
data are reported.
Table 2. HDL-C and TG levels (means, standard deviations, range; mmol/L) measured before the first
LA session in both groups.
CVEx/0 CVEx/1+
HDL-C_1LA 1.44 ± 0.36 1.42 ± 0.54
range 0.72–2.42 0.34–3.71
TG_1LA 1.98 ± 2.17 1.93 ± 1.26
range 0.42–15.63 0.56–5.74
Clearly, some patients had a combined hyperlipoproteinemia with elevations of TG as well.
The HDL-C values were low in some patients, in others extremely high. In the ANOVA testing,
no difference was shown between the two CVE-Groups.
3.3. LA Methods Used
As mentioned in the methods section, six LA methods have been used (Table 3).
Age at start of the LA therapy, LDL-Cpre, LDL-CIM, Lp(a)pre, Lp(a)post, CVEsbef, and CVEsdur
were not different between the LA methods subgroups. Figure 4 provides an information about the
distribution of the LA methods among the two CVE-Groups.
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Table 3. Numbers of patients treated with an LA method in May 2019. Parameters which were
significantly different are listed: duration of LA therapy (mean, range), LDL-Cpost (after the LA session
in 2019; mean ± standard deviation) LDL-Cpost: only the HELP and die Liposorber D groups were
significantly different (Bonferroni-test: p 0.020).
LA Method Numbers of Patients Treatment (Years) LDL-Cpost (mmol/L)
HELP 15 4.67 (range: 1.4–9.32) 0.93 ± 0.53
Lipid filtration 23 5.33 (range: 1.48–16.7) 0.69 ± 0.31
MONET 18 4.84 (range: 1.41–10.99) 0.64 ± 0.32
DALI 15 8.81 (range: 1.25–26.24) 0.71 ± 0.38
Liposorber D 25 5.68 (range: 1.67–11.09) 0.56 ± 0.25
TheraSorbTMLDL 12 4.46 (range: 1.41–14.73) 0.54 ± 0.24
 
Figure 4. Number of patients treated with an LA method in the two groups CVEx/0 and CVEx/1+
(Abbreviations: Th_LDL TheraSorbTMLDL, LipoD Liposorber D, LF lipid filtration).
The small numbers of patients in the subgroups of LA methods do not allow any final conclusions
with respect to the effect of different LA methods on outcome data.
4. Discussion
The major findings in this investigation are that an older age at the start of the LA therapy
and a higher number of CVEs in the history are associated with the incidence of CVEs during the
extracorporeal treatment.
LDL-C and Lp(a) concentrations either measured initially nor before and after the LA sessions did
not seem to have an influence. Of course, we were trying to optimize the acute reduction rates of both
lipid fractions by modifying the treated volume of whole blood or plasma, by switching the patient
to another LA method, and/or by optimizing the lipid-lowering drug therapy. In both groups the
number of patients taking a statin was slightly decreased during the follow-up (most probably because
of tolerance problems), whereas PCSK9 inhibitors were newly started in some patients, especially in
Group CVEx/1+.
In the Pro(a)Life study when comparing with our data, patients suffered from a lower number of
CVEs before the extracorporeal therapy, their mean age at the start of the LA therapy was 57 years (that
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is in the mean between the mean ages of our CVE-Groups). All CVEs were reduced by 75.9% when
comparing the time periods 2 years before and during LA therapy. [3] The somewhat lower reduction
rate of CVEs in our study may be explained by the longer observation time and the somewhat higher
mean age in Group CVEx/1+.
In 2013, we had published a study in 64 apheresis patients, 20 of them developed new CVEs
during LA therapy. [7] Among those with events there were relatively more males and relatively more
old patients, the percentage of patients with elevated Lp(a) levels was higher, patients had suffered
from more peripheral arterial occlusions and (re-)stenosis, and carotid artery stenosis (whereas other
CVEs were not different from the other group without events). Mean lipid concentrations before and
after LA were not different with the exception of higher LDL-Cpre levels in those patients who did not
have new CVEs.
In the 2019 ESC/EAS Guidelines, a target LDL-C lower than 1.4 mmol/L (55 mg/dL) has been
recommended for high risk patients. [12] The actual LDL-CIM values reflect the lipid load of the
patients when treated extracorporeally. In Group CVEx/0 only 12 patients (20%) exhibited an LDL-CIM
below 1.4 mmol/, in 28 patients (46.7%) the LDL-CIMcorr was below this level. The corresponding
percentages for Group CVEx/1+were: 20 patients (41.7%) (LDL-CIM) below 1.4 mmol/L and 31 patients
(64.6%) (LDL-CIMcorr).
On the other hand, even rather low LDL-C concentrations do not guarantee an event-free future.
This explains why in this guideline the authors recommend for patients with atherosclerotic vascular
disease who experience a second vascular event within 2 years (not necessarily of the same type as the
first event) while taking maximally tolerated statin-based therapy, an LDL-C goal of < 1.0 mmol/L
(<40 mg/dL). The latter are patients in need for an LA therapy. Our data clearly point to the fact
that the latter target can hardly be reached even in maximally treated patients. In Group CVEx/0 2
patients (3.3%) did not exceed this target (LDL-CIM) and 12 patients (25%) (LDL-CIMcorr), respectively.
The data for Group CVEx/1+were: 9 patients (18.8%) (LDL-CIM) and 17 patients (35.4%) (LDLCIMcorr).
The data show that in Group CVEx/1+ the percentages were even higher than in the Group without
new events during LA (CVEx/0).
For Lp(a) no therapeutic target values have been officially recommended up to now. In actuality,
120 (or higher) nmol/L is the officially accepted Lp(a) level for the indication to start an LA therapy in
Germany [6]. In Group CVEx/0 the Lp(a)IM value was below 120 nmol/L (is equal to about 50 mg/dL)
in 30 patients (50%), in Group CVEx/1+ in 21 patients (43.8%). The National Lipid Association defined
a concentration of more than 100 nmol/L of Lp(a) as a risk-enhancing factor [13]. The mean Lp(a)IM
values in both groups of this evaluation were higher than 100 nmol/L. When comparing the Lp(a) levels
at the start of the LA therapy with the Lp(a)IM concentrations, in both groups a reduction by about
120 nmol/L was observed. Evidently, this reduction does not explain the difference in the occurrence
of CVEs in these groups. It is not possible to interpret data obtained in Mendelian randomization
analysis [13] with respect to lowering Lp(a) and its impact on cardiovascular outcome data from the
point of view of the extracorporeal treatment.
LA methods may be different with respect to their pleiotropic effects [11]. The clinical relevance
of these effects is still quite unclear. In the prospective Pro(a)Life Study, no difference with respect
to outcome data has been detected when considering the various LA methods used. The differing
distribution of LA methods in the two CVEs Groups in our evaluation which is depicted in Figure 4
evokes the suspicion that there could be some effects with respect to the occurrence of new events.
However, the numbers in the subgroups are still rather small, and moreover the retrospective character
of our study limits the significance of conclusions in this respect.
5. Conclusions
An LA therapy should be started earlier—already after 2 CVEs (or even only one) have occurred.
The probability of new events will be higher when more than 3 CVEs have happened. Younger patients
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will have a higher benefit from the extracorporeal therapy. In the older patients, the atherosclerotic
lesions may be more pronounced and may be more prone to develop complications.
The topic of this manuscript remains to be actual—future studies should include more patients
(and could be done within the framework of the German Lipoprotein Apheresis Registry, where starting
from January 2020 the LA methods have to be documented) [14]. Data looking at different apo(a)
isoforms or genetic findings could be of interest.
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